Reporting owner · CIK 0001233253

Hanish Arnold C

Visual SEC Form 4 history across 3 companies, 12 transactions and 3 filings.

DIRDecoy Therapeutics Inc.
Open-market mix
Filings3Form 4 records
Buying$00 purchases
Selling$282.1K5 sales
Net value−$282.1KBuys minus sells
Companies32 securities
Most recentAug 31, 2026grant

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-52Dec 253Aug 26

Net value flow

Buys minus sells

Dec 25
−$17.3
Aug 26
−$282.1K

Transaction texture

Ownership and ticket size

Average P/S size$56.4K
Median P/S size$92.6K
Direct11
Indirect1
Aug 31, 2026grant

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at OMEROS CORP on Aug 27, 2026 valued at $95,081.

Review SEC filing
Latest buy

No open-market insider purchase is available.

TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
SLRXHANISH ARNOLD C
DIR
sale12-$768S0.0%01/0212/30/2025
SLRXHANISH ARNOLD C
DIR
sale15-$960S0.0%01/0212/30/2025

Hanish Arnold C Insider Activity FAQ

SEC Form 4 context

Who is Hanish Arnold C?

Hanish Arnold C is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001233253.

Which companies has Hanish Arnold C reported transactions for?

Decoy Therapeutics Inc., OMEROS CORP, Salarius Pharmaceuticals, Inc.

When was Hanish Arnold C's latest insider buy?

No open-market insider purchase is available for this period.

When was Hanish Arnold C's latest insider sale?

sale at OMEROS CORP on Aug 27, 2026 valued at $95,081.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.